— Know what they know.
Not Investment Advice

SBTX NASDAQ

Silverback Therapeutics, Inc.
1W: -4.5% 1M: +16.5% 3M: +16.7% 1Y: -33.3%
$5.87
Last traded 2022-11-08 — delisted
NASDAQ · Healthcare · Biotechnology · $550.4M mcap · 12M float · 1.48% daily turnover

Balance Sheet Trends

Total Assets
$328M -6.7% ▼
5Y CAGR: +65.5%
Total Liabilities
$213M +126.2% ▲
5Y CAGR: +39.5%
Shareholders Equity
$114M -55.5% ▼
5Y CAGR: +73.9%
Cash & Investments
$245M -22.0% ▼
5Y CAGR: +58.5%
Total Debt
$0 -100.0% ▼
Net Debt
-$41M +18.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$60M$211M$71M$51M$41M
Short-Term Investments$0$64M$157M$263M$204M
Cash & ST Investments$60M$274M$228M$314M$245M
Net Receivables$1K$1M$795K$9M$25M
Inventory$0$0$0$5M$8M
Other Current Assets$0$0$163K$1M$6M
Total Current Assets$61M$278M$232M$334M$285M
Property, Plant & Equip.$693K$774K$824K$1M$2M
Goodwill & Intangibles$0$0$617K$7M$14M
Long-Term Investments$65M$0$0$0$0
Other Non-Current Assets-$65M$3M$21K$8M$26M
Total Non-Current Assets$716K$4M$1M$17M$43M
Total Assets$61M$281M$233M$351M$328M
— Liabilities —
Accounts Payable$2M$2M$759K$10M$0
Short-Term Debt$3M$230K$237K$42K$0
Deferred Revenue$1M$283K$0$557K$0
Other Current Liabilities$660K$3M$843K$2M$39M
Total Current Liabilities$8M$5M$2M$23M$39M
Long-Term Debt$5M$0$0$0$0
Other Non-Current Liab.$76M$3M$0$71M$174M
Total Non-Current Liabilities$85M$3M$37K$71M$174M
Total Liabilities$93M$9M$2M$94M$213M
— Equity —
Common Stock$3K$9K$10K$10K$10K
Retained Earnings-$42M-$77M-$131M-$123M-$295M
Accumulated OCI-$326K$407K$49K$220K$0
Total Stockholders Equity-$31M$273M$231M$257M$114M
Total Liabilities & Equity$61M$281M$233M$351M$328M
— Key Metrics —
Total Debt$9M$481K$274K$42K$0
Net Debt-$51M-$210M-$71M-$51M-$41M
Total Investments$65M$64M$157M$263M$204M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms